tirzepatide mash fda FDA approved Madrigal's Resmetirom (Rezdiffra®) as first drug treatment for MASH. What now? FDA Approves Wegovy For Metabolic

By stimulating GLP-1 and GIP receptors simultaneously, tirzepatide slows stomach emptying, increases satiety hormones, and reduces overall appetite drive

Since November, 2023, empagliflozin is now indicated in people aged 10 years as a monotherapy if metformin is not tolerated (and diet and exercise alone do not provide adequate glycaemic control), or in combination with other glucose-lowering medicines (under specialist supervision) if glycaemic control remains poor

The scientific community, generally speaking, has guardrails on whats considered a rigorous way to do this

Losing just 10% of your overall body weight can significantly reduce joint pain and restore function

Poor Skincare/Hydration: Poor skin care habits and lack of hydration can also cause dull skin